Results 41 to 50 of about 73,607 (303)

GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC

OncoImmunology, 2017
Programmed death ligand 1 (PD-L1) functions as a key immune inhibitory factor by binding with its receptor, programmed death 1 (PD-1), to induce immune cell dysfunction and escape of the immune system.
Chengzhong Lin, Wei Cao, Zhenhu Ren, Yu Tang, Chunye Zhang, Rong Yang, Yiming Chen, Zheqi Liu, Canbang Peng, Lizhen Wang, Xu Wang, Tong Ji   +11 more
doaj   +1 more source

Myelofibrosis, JAK2 inhibitors and erythropoiesis [PDF]

Leukemia, 2013
The term myeloproliferative disorders was introduced by William Dameshek1 in 1951 to describe four different diseases with a related pathogenesis: polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF) and chronic myeloid leukaemia. The discovery of the Philadelphia chromosome and the fusion gene BCR-ABL has permitted the
W, Vainchenker, F, Favale
openaire   +2 more sources

Progressive optic neuropathy secondary to JAK2 mutation-positive myeloproliferative neoplasm

Indian Journal of Ophthalmology. Case Reports, 2022
We describe a 25-year-old male presenting with chronic papilledema due to cerebral venous sinus thrombosis (CVST) and was found to have a myeloproliferative disorder with JAK2 mutation. All measures to salvage vision were unfruitful from transverse sinus
Swetha Komma, Selvakumar Ambika, Veena O Noronha, Deepak Arjundas   +3 more
doaj   +1 more source

Therapeutic potential of JAK2 inhibitors [PDF]

Hematology, 2009
AbstractThe discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clinical studies.
openaire   +2 more sources

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies

Oncotarget, 2011
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in
PASSAMONTI, FRANCESCO, Maffioli M, Caramazza D, Cazzola M.   +3 more
openaire   +4 more sources

Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis

Avicenna Journal of Medicine, 2014
Hepatosplenic T-cell lymphoma (HSTL) is a rare T-cell neoplasm of the lymphoid system. This type of lymphoma is characterized by sinusoidal infiltration of spleen, liver, bone marrow and lymph nodes by neoplastic lymphocytes.
Ali M Gabali, Tarek Jazaerly, Chung-Che Jeff Chang, Ronald Cleveland, Lawrence Kass   +4 more
doaj   +1 more source

Regulation of the Glutamate Transporters by JAK2 [PDF]

Cellular Physiology and Biochemistry, 2011
The Janus-activated kinase-2 JAK2 is involved in the signaling of leptin and erythropoietin receptors and mediates neuroprotective effects of the hormones. In theory, JAK2 could be effective through modulation of the glutamate transporters, carriers accounting for the clearance of glutamate released during neurotransmission.
Zohreh, Hosseinzadeh, Shefalee K, Bhavsar, Mentor, Sopjani, Ioana, Alesutan, Ambrish, Saxena, Miribane, Dërmaku-Sopjani, Florian, Lang   +6 more
openaire   +2 more sources

JAK2, STAT3 Gene Polymorphisms in Turkish Patients with Behçet’s Disease

Gazi Medical Journal
Objective: Behçet’s disease (BD) is a chronic, multisystemic inflammatory disorder with an unknown etiology. T cells are crucial in the pathogenesis of BD.
Darya Farhoomand Aksoy, Rahime Aksoy, Sevim Gönen, Ümit Ölmez   +3 more
doaj   +1 more source

CALR mutation profile in Irish patients with myeloproliferative neoplasms

Hematology/Oncology and Stem Cell Therapy, 2016
Insertion and/or deletion mutations of the CALR gene have recently been demonstrated to be the second most common driver mutations in the myeloproliferative neoplasms (MPNs) of essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Karl Haslam, Eibhlin Conneally, Catherine M. Flynn, Mary R. Cahill, Oonagh Gilligan, Derville O'Shea, Stephen E. Langabeer   +6 more
doaj   +1 more source

PREFERENTIAL NUCLEAR ACCUMULATION OF JAK2V617F IN CD34+ BUT NOT IN GRANULOCYTIC, MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA.

, 2010
Recently, Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from chromatin and resulting in a disregulation of several JAK2-regulated genes such
Fabrizio Pane, Vincenzo Martinelli, Vitalyi Senyuk, Giuseppina Nucifora, Rinaldi, Ciro Roberto, Paola Rinaldi, Ciro R. Rinaldi, Marica Gemei, Fabio Formiggini, Nicola Esposito, Adele Alagia   +10 more
core   +1 more source